Every material Form 8-K Enliven Therapeutics, Inc. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Enliven Therapeutics reported a third-quarter 2026 net loss of $27.7 million, up from $20.1 million a year earlier, as research and development and general and administrative expenses rose. The company said it reached alignment with the FDA on the final design of its ENABLE-2 pivotal Phase 3 trial and remains on track to start the trial before year-end 2026, with $884.4 million in cash, cash equivalents and marketable securities expected to fund operations into 2030.
Q3 2026 net loss was $27.7 million, or $0.36 per share, versus $20.1 million, or $0.32 per share, in Q3 2025
R&D expenses were $28.0 million in Q3 2026, compared with $18.2 million in Q3 2025
Cash, cash equivalents and marketable securities totaled $884.4 million as of September 30, 2026, with runway expected into 2030
ENABLE-2 start is targeted before year-end 2026 following FDA alignment on trial design
Enliven Therapeutics appointed Kristine Ball as a Class II director and Audit Committee member, effective October 14, 2026, expanding the board from seven to eight directors. The company says the appointment comes as it prepares to start the pivotal Phase 3 ENABLE-2 trial of relcobatinib before year-end 2026, a routine governance change with no financial results disclosed.
Kristine Ball appointed Class II director, term expiring at the 2028 annual meeting, and Audit Committee member, effective October 14, 2026
Ball receives $45,000 per year as an outside director and $10,000 per year for Audit Committee service
Initial stock option grant with a grant date fair value of approximately $650,000, vesting monthly over 36 months
Company plans to initiate the Phase 3 ENABLE-2 trial of relcobatinib before year-end 2026
Enliven Therapeutics reported a second-quarter 2026 net loss of $32.5 million, up from $25.3 million a year earlier, as research and development expenses rose to $29.0 million from $21.5 million. The company had $895.2 million in cash, cash equivalents and marketable securities at June 30, 2026, which it expects to provide cash runway into 2030. It also said it reached alignment with the FDA on key components of the Phase 3 ENABLE-2 trial design for ELVN-001, with the Phase 3 trial expected to start in the second half of 2026.
Net loss of $32.5 million in Q2 2026 vs. $25.3 million in Q2 2025; net loss per share of $0.49 in both periods
R&D expenses $29.0 million vs. $21.5 million; G&A expenses $8.2 million vs. $7.1 million
Cash, cash equivalents and marketable securities of $895.2 million at June 30, 2026, up from $462.6 million at December 31, 2025
FDA selected 80 mg once daily as the recommended Phase 3 dose; End-of-Phase 2 meeting anticipated in Q3 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Enliven Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →